Synthesis and evaluation of a new phosphorylated ribavirin prodrug

Antiviral Research

Volumn 99, Issue 1, 2013, Pages 18-26

  Dong, Steven D ^a   Lin, Chin Chung ^a   Schroeder, Mel ^b  

^a Epiphany Biosciences Inc   (United States)

^b Kalexsyn Inc   (United States)

Author keywords

Antiviral drug; Cellular uptake; Hepatitis C virus; Prodrug; Red blood cell; Ribavirin

Indexed keywords

ADENOSINE TRIPHOSPHATE; PRODRUG; RIBAVIRIN;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG SCREENING; DRUG SYNTHESIS; DRUG UPTAKE; ERYTHROCYTE; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA VIRUS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPLICON; TISSUE DISTRIBUTION;

HEPATITIS C VIRUS; ORTHOMYXOVIRIDAE; RATTUS;

EID: 84878144500     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2013.04.014     Document Type: Article

References (35)

1. Bengsch, B., Thimme, R., 2010. Ribavirin ante portas: uptake transporters into hepatocytes dissected. J. Hepatol. 52, 469-471.
2. Blight, K.J., Kolykhalov, A.A., Rice, C.M., 2000. Efficient initiation of HCV RNA replication in cell culture. Science 290, 1972-1974.
3. Crotty, S., Cameron, C., Andino, R., 2002. Ribavirin's antiviral mechanism of action: lethal mutagenesis? J. Mol. Med 80, 86-95.
4. Dadgostari, S., Xu, C., Yeh, L.-T., Lin, C.C., Vitarella, D., 2004. Viramidine demonstrates better safety than ribavirin in monkeys but not rats. Drug. Chem. Toxicol. 27, 191-211.
5. De Franceschi, L., Fattovich, G., Turrini, F., Ayi, K., Brugnara, C., Manzato, F., Noventa, F., Stanzial, A.M., Solero, P., Corrocher, R., 2000. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 31, 997-1004.
6. Di Pierro, D., Tavazzi, B., Perno, C.F., Bartolini, M., Balestra, E., Calió, R., Giardina, B., Lazzarino, G., 1995. An ion-pairing high-performance liquid chromatographic method for the direct simultaneous determination of nucleotides, deoxynucleotides, nicotinic coenzymes, oxypurines, nucleosides, and bases in perchloric acid cell extracts. Anal. Biochem. 231, 407-412.
7. Dixit, N.M., Perelson, A.S., 2006. The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus. Cell. Mol. Life Sci. 63, 832-842.
8. Feld, J.J., 2012. Is there a role for ribavirin in the era of hepatitis C virus direct-acting antivirals? Gastroenterology 142, 1356-1359.
9. Fletcher, T., Ptak, R., Bartram, S., Halliday, S., Buckheit, R., Moravec, R., Riss, T., 2000. A HTS system for screening antiviral compounds using the cell Titer® 96 aqueous one solution assay. Promega Notes 75, 13-16.
10. Fukuchi, Y., Furihata, T., Hashizume, M., Iikura, M., Chiba, K., 2010. Characterization of ribavirin uptake systems in human hepatocytes. J. Hepatol. 52, 486-492.
11. He, G.-X., Krise, J.P., Oliyai, R., 2007. Prodrugs of phosphonates, phosphinates, and phosphates. In: Stella, V.J., Borchardt, R.T., Hageman, M.J., Oliyai, R., Maag, H., Tilley, J.W. (Eds.), Prodrugs. Springer, New York, NY, pp. 923-964.
12. Hostetler, K.Y., Beadle, J.R., Hornbuckle, W.E., Bellezza, C.A., Tochkov, I.A., Cote, P.J., Gerin, J.L., Korba, B.E., Tennant, B.C., 2000. Antiviral activities of oral 1-Ohexadecylpropanediol- 3-phosphoacyclovir and acyclovir in woodchucks with chronic woodchuck hepatitis virus infection. Antimicrob. Agents Chemother. 44, 1964-1969.
13. Hostetler, K.Y., Rybak, R.J., Beadle, J.R., Gardner, M.F., Aldern, K.A., Wright, K.N., Kern, E.R., 2001. In vitro and in vivo activity of 1-O-hexadecylpropanediol-3-phosphoganciclovir and 1-O-hexadecylpropanediol-3-phospho-penciclovir in cytomegalovirus and herpes simplex virus infections. Antivir. Chem. Chemother. 12, 61-70.
14. Hostetler, Karl Y., 2009. Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. Antiviral Res. 82, A84-98.
15. Hostetler, Karl Y., 2010. Synthesis and early development of hexadecyloxypropylcidofovir: an oral antipoxvirus nucleoside phosphonate. Viruses 2, 2213- 2225.
16. Ibarra, K.D., Pfeiffer, J.K., 2009. Reduced ribavirin antiviral efficacy via nucleoside transporter-mediated drug resistance. J. Virol. 83, 4538-4547.
17. Iikura, M., Furihata, T., Mizuguchi, M., Nagai, M., Ikeda, M., Kato, N., Tsubota, A., Chiba, K., 2012. ENT1, a ribavirin transporter, plays a pivotal role in antiviral efficacy of ribavirin in a hepatitis C virus replication cell system. Antimicrob. Agents Chemother. 56, 1407-1413.
18. Inoue, Y., Homma, M., Matsuzaki, Y., Shibata, M., Matsumura, T., Ito, T., Kohda, Y., 2006. Erythrocyte ribavirin concentration for assessing hemoglobin reduction in interferon and ribavirin combination therapy. Hepatol. Res. 34, 23-27.
19. Korba, B.E., Gerin, J.L., 1992. Use of a standardized cell culture assay to assess activities of nucleoside analogs against hepatitis B virus replication. Antiviral Res. 19, 55-70.
20. Lau, J., Hong, Z., 2004. Methods of drug delivery to hepatocytes and treatment of flaviviridae infections [WWW Document]. http://patentscope.wipo.int/search/en/WO2002015904 (accessed 5.23.12).
21. Lin, C., Yeh, L.-T., Vitarella, D., Hong, Z., 2003a. Viramidine, a prodrug of ribavirin, shows better liver-targeting properties and safety profiles than ribavirin in animals. Antivir. Chem. Chemother. 14, 145-152.
22. Lin, C.-C., Luu, K., Lourenco, D., Yeh, L.-T., 2003b. Pharmacokinetics and metabolism of [14C]viramidine in rats and cynomolgus monkeys. Antimicrob. Agents Chemother. 47, 2458-2463.
23. Matsuoka, Y., Lamirande, E.W., Subbarao, K., 2009. The mouse model for influenza. In: Coico, R., Kowalik, T., Quarles, J., Stevenson, B., Taylor, R. (Eds.), Current Protocols in Microbiology. John Wiley & Sons, Inc., Hoboken, NJ, USA.
24. Okuse, C., Rinaudo, J.A., Farrar, K., Wells, F., Korba, Brent.E., 2005. Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy. Antiviral Res. 65, 23-34.
25. Paeshuyse, J., Dallmeier, K., Neyts, J., 2011. Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action. Curr. Opin. Virol. 1, 590-598.
26. Page, T., Connor, J.D., 1990. The metabolism of ribavirin in erythrocytes and nucleated cells. Int. J. Biochem. 22, 379-383.
27. Parker, W.B., 2005. Metabolism and antiviral activity of ribavirin. Virus Res. 107, 165-171.
28. Pockros, P.J., 2010. New direct-acting antivirals in the development for hepatitis C virus infection. Therap. Adv. Gastroenterol. 3, 191-202.
29. Randall, G., Grakoui, A., Rice, Charles M., 2003. Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs. PNAS 100, 235-240.
30. Russmann, S., Grattagliano, I., Portincasa, P., Palmieri, V.O., Palasciano, G., 2006. Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research. Curr. Med. Chem. 13, 3351-3357.
31. Selle, H., Chapman, B.E., Kuchel, P.W., 1992. Release of choline by phospholipase D and a related phosphoric diester hydrolase in human erythrocytes. 1H spin-echo n.m.r. studies. Biochem. J. 284 (Pt. 1), 61-65.
32. Shiffman, M.L., 2009. What future for ribavirin? Liver Int. 29 (Suppl. 1), 68-73.
33. Sidwell, R.W., Huffman, J.H., Khare, G.P., Allen, L.B., Witkowski, J.T., Robins, R.K., 1972. Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 177, 705-706.
34. Vermehren, J., Sarrazin, C., 2011. New HCV therapies on the horizon. Clin. Microbiol. Infect. 17, 122-134.
35. Yeh, L.-T., Nguyen, M., Lourenco, D., Lin, C.-C., 2005. A sensitive and specific method for the determination of total ribavirin in monkey liver by high-performance liquid chromatography with tandem mass spectrometry. J. Pharm. Biomed. Anal. 38, 34-40.